Table 2.
Antimicrobial susceptibility test results for teicoplanin and vancomycin in S. epidermidis from 2016 to 2021.
| Year | ||||||
|---|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
| Glycopeptide antibiotic MICs, median (IQR) (mg/L) | ||||||
| Teicoplanin | 4 (4–8) | 4 (4–8) | 4 | 4 (2–8) | 4 (2–8) | 8 (4–16) |
| Vancomycin | 2 (1–2) | 2 (1–2) | 2 | 2 (1–2) | 2 (1–2) | 1 (1–2) |
| Number of isolates with respect to teicoplanin MIC values, N (%) | ||||||
| MIC < 16 mg/La | ||||||
| MIC < 8 mg/L | 58 (69.9) | 42 (77.8) | 56 (77.8) | 40 (72.7) | 13 (72.2) | 16 (40.0) |
| MIC = 8 mg/L | 24 (28.9) | 15 (25.0) | 16 (22.2) | 15 (27.3) | 5 (27.8) | 11 (26.5) |
| MIC ≥ 16 mg/Lb | 1 (1.2) | 3 (5.0) | 0 | 0 | 0 | 13 (32.5) |
Teico-S teicoplanin-susceptible, Teico-NS teicoplanin-non-susceptible, MIC minimal inhibitory concentration, IQR interquartile range.
aTeico-S group.
bTeico-NS group.